Marta Lalinde-Gutiérrez

Marta Lalinde-Gutiérrez

Auto-generated profile, based on publicly available information

Marta Lalinde-Gutiérrez

Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2024 in Nature Cancer
Verified
Journal Article
Open access
PDF file
SCSelim Chaib
Selim Chaib
JLJosé Alberto López-Domínguez
José Alberto López-Domínguez
MLMarta Lalinde-Gutiérrez
Marta Lalinde-Gutiérrez
NPNeus Prats
Neus Prats
IMInes Marin
Ines Marin
MSManuel Serrano
Manuel Serrano
Chemotherapy often generates intratumoral senescent cancer cells that strongly modify the tumor microenvironment, favoring immunosuppression and tumor growth. We discovered, through an unbiased proteomics screen, that the immune checkpoint inhibitor programmed cell death 1 ligand 2 (PD-L2) is highly upregulated upon induction of senescence in different types of cancer cells. PD-L2 is not required for cells to undergo senescence, but it is critical for senescent cells to evade the immune system and persist intratumorally. Indeed, after chemotherapy, PD-L2-deficient senescent cancer cells are rapidly eliminated and tumors do not produce the senescence-associated chemokines CXCL1 and CXCL2. Accordingly, PD-L2-deficient pancreatic tumors fail to recruit myeloid-derived suppressor cells and undergo regression driven by CD8 T cells after chemotherapy. Finally, antibody-mediated blockade of PD-L2 strongly synergizes with chemotherapy causing remission of mammary tumors in mice. The combination of chemotherapy with anti-PD-L2 provides a therapeutic strategy that exploits vulnerabilities arising from therapy-induced senescence.

12 October 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
SDSantiago Duro-Sánchez
Santiago Duro-Sánchez
MNMercedes Nadal
Mercedes Nadal
MLMarta Lalinde-Gutiérrez
Marta Lalinde-Gutiérrez
Enrique Javier ArenasEnrique Javier Arenas
Enrique Javier Arenas
CMCristina Bernadó. Bernadó Morales
Cristina Bernadó. Bernadó Morales
Joaquín ArribasJoaquín Arribas
Joaquín Arribas
Antibody–drug conjugates (ADC) are antineoplastic agents recently introduced into the antitumor arsenal. T-DM1, a trastuzumab-based ADC that relies on lysosomal processing to release the payload, is approved for HER2-positive breast cancer. Next-generation ADCs targeting HER2, such as [vic-]trastuzumab duocarmazine (SYD985), bear linkers cleavable by lysosomal proteases and membrane-permeable drugs, mediating a bystander effect by which neighboring antigen-negative cells are eliminated. Many antitumor therapies, like DNA-damaging agents or CDK4/6 inhibitors, can induce senescence, a cellular state characterized by stable cell-cycle arrest. Another hallmark of cellular senescence is the enlargement of the lysosomal compartment. Given the relevance of the lysosome to the mechanism of action of ADCs, we hypothesized that therapies that induce senescence would potentiate the efficacy of HER2-targeting ADCs. Treatment with the DNA-damaging agent doxorubicin and CDK4/6 inhibitor induced lysosomal enlargement and senescence in several breast cancer cell lines. While senescence-inducing drugs did not increase the cytotoxic effect of ADCs on target cells, the bystander effect was enhanced when HER2-negative cells were cocultured with HER2-low cells. Knockdown experiments demonstrated the importance of cathepsin B in the enhanced bystander effect, suggesting that cathepsin B mediates linker cleavage. In breast cancer patient-derived xenografts, a combination treatment of CDK4/6 inhibitor and SYD985 showed improved antitumor effects over either treatment alone. These data support the strategy of combining next-generation ADCs targeting HER2 with senescence-inducing therapies for tumors with heterogenous and low HER2 expression. Significance: Combining ADCs against HER2-positive breast cancers with therapies that induce cellular senescence may improve their therapeutic efficacy by facilitating a bystander effect against antigen-negative tumor cells.

4 November 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
SCSelim Chaib
Selim Chaib
JLJosé Alberto López-Domínguez
José Alberto López-Domínguez
MLMarta Lalinde
Marta Lalinde
NPNeus Prats
Neus Prats
IMInes Marin
Ines Marin
MSManuel Serrano
Manuel Serrano
Anti-cancer therapies often result in a subset of surviving cancer cells that undergo therapy-induced senescence (TIS). Senescent cancer cells strongly modify the intratumoural microenvironment favoring immunosuppression and, thereby, tumour growth. An emerging strategy to optimise current therapies is to combine them with treatments that eliminate senescent cells. To this end, we undertook an unbiased proteomics approach to identify surface markers contributing to senescent cells immune evasion. Through this approach, we discovered that the immune checkpoint inhibitor PD-L2, but not PD-L1, is upregulated across multiple senescent human and murine cells. Importantly, blockade of PD-L2 strongly synergises with genotoxic chemotherapy, causing remission of solid tumours in mice. We show that PD-L2 inhibition prevents the persistence of chemotherapy-induced senescent cells, which exert cell-extrinsic immunomodulatory actions. In particular, upon chemotherapy, tumours deficient in PD-L2 fail to produce cytokines of the CXCL family, do not recruit myeloid-derived suppressor cells (MDSCs) and are eliminated in a CD8 T cell-dependent manner. We conclude that blockade of PD-L2 improves chemotherapy efficacy by reducing the intratumoural burden of senescent cells and their associated recruitment of immunosuppressive cells. These findings provide a novel strategy to exploit vulnerabilities arising in tumour cells as a result of therapy-induced damage and cellular senescence.

2 January 2026 in Science Advances
Verified
Journal Article
Open access
MLMarta Lalinde-Gutiérrez
Marta Lalinde-Gutiérrez
SPSandra Pérez-Ramos
Sandra Pérez-Ramos
VRVeronica Rodilla
Veronica Rodilla
PBPau Garcia Baucells
Pau Garcia Baucells
JPJúlia Perera-Bel
Júlia Perera-Bel
Joaquín ArribasJoaquín Arribas
Joaquín Arribas
Cells terminally arrested in the cell cycle that exhibit a distinct secretory phenotype are referred to as senescent. These cells play a complex role during tumor progression; they can inhibit or promote tumor growth depending on disease stage. We developed a mouse model that allows monitoring and selective elimination of cells expressing high levels of the cyclin-dependent kinase inhibitor p16 and interleukin-6. These mice, termed SuSe (suicidal senescence), were crossed with the mouse mammary tumor virus–polyomavirus middle T antigen (MMTV-PyMT) model of breast cancer. Functional characterization in SuSe/PyMT mice confirmed that depletion of senescent cells (senolysis) in early and late lesions accelerated and decelerated tumor growth and metastasis, respectively. Tumor acceleration was attributed to expansion of immunosuppressive, protumorigenic macrophages. C-C motif chemokine ligand 2 was identified as an autocrine chemokine essential for their recruitment and maintenance. Depletion of these macrophages reversed the effects of senescent cell clearance, rendering senolysis antitumorigenic even at early stages. Our results suggest that targeting immunosuppressive macrophages can preserve the benefits of senolysis while mitigating adverse effects.


24 November 2025
Verified
Other
Open access
SDSantiago Duro-Sánchez
Santiago Duro-Sánchez
MNMercedes Nadal
Mercedes Nadal
MLMarta Lalinde-Gutiérrez
Marta Lalinde-Gutiérrez
Enrique Javier ArenasEnrique Javier Arenas
Enrique Javier Arenas
CMCristina Bernadó Morales
Cristina Bernadó Morales
Joaquín ArribasJoaquín Arribas
Joaquín Arribas
Effect of different inducers of senescence on the bystander effect of ADCs.